Corporate Office HQ

Medical

MEDNAX Corporate Office

MEDNAX was founded as Pediatrix Medical Group in 1979. MEDNAX was founded in 2009 by Dr. Roger Medel.

Today MEDNAX is the holding company for three business units: Pediatrix Medical Group, American Anesthesiology, and Mednax Service, as well as a network of 2,500 physicians, practitioners, and specialists who focus on children and women’s health.

MEDNAX is the largest provider of newborn hearing screening exams.

The company also conducts clinical research and offers administrative services to physicians and hospitals in the areas of billing, recruiting, risk management, staffing, and compliance.

MEDNAX trades publicly on the New York Stock Exchange under the ticker symbol MD, is #928 in the Fortune 1000, has 15,900 employees, and had $3.46 billion in revenue in 2017.

MEDNAX

MEDNAX was founded as Pediatrix Medical Group in 1979. MEDNAX was founded in 2009 by Dr. Roger Medel.

Today MEDNAX is the holding company for three business units: Pediatrix Medical Group, American Anesthesiology, and Mednax Service, as well as a network of 2,500 physicians, practitioners, and specialists who focus on children and women’s health.

MEDNAX is the largest provider of newborn hearing screening exams.

History

The company also conducts clinical research and offers administrative services to physicians and hospitals in the areas of billing, recruiting, risk management, staffing, and compliance.

MEDNAX trades publicly on the New York Stock Exchange under the ticker symbol MD, is #928 in the Fortune 1000, has 15,900 employees, and had $3.46 billion in revenue in 2017.

Regeneron Pharmaceuticals Corporate Office

Regeneron Pharmaceuticals is a biotechnology company founded in 1988 which originally focused on neurotrophic factors and their regenerative capabilities. Neurotrophic factors are a family of proteins that may be capable of regrowing damaged neurons.

The company has three products on the market: EYLEA, which treats elderly blindness, ARCALYST, which treats certain pediatric and neonatal inflammatory diseases, and ZALTRAP, for metastatic colorectal cancer.

Regeneron Pharmaceuticals trades publicly on the NASDAQ under the ticker symbol REGN, is #364 in the FT Gloabl 500, is #943 in the Fortune 1000, has 3,066 employees, and had $3.06 billion in revenue in 2014.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biotechnology company founded in 1988 which originally focused on neurotrophic factors and their regenerative capabilities. Neurotrophic factors are a family of proteins that may be capable of regrowing damaged neurons.

The company has three products on the market: EYLEA, which treats elderly blindness, ARCALYST, which treats certain pediatric and neonatal inflammatory diseases, and ZALTRAP, for metastatic colorectal cancer.

Regeneron Pharmaceuticals trades publicly on the NASDAQ under the ticker symbol REGN, is #364 in the FT Gloabl 500, is #943 in the Fortune 1000, has 3,066 employees, and had $3.06 billion in revenue in 2014.

History

Health Care Property Investors Corporate Office

Health Care Property Investors is a real-estate investment trust (REIT) that was founded in 1985. The company originally invested primarily in health care real estate. Hospitals and Post-Acute Care facilities were in the original portfolio.

Today Health Care Property Investors (HCP) invests in, develops, manages, and leases health care properties in 40 U.S. states and Mexico.

Its real estate portfolio consists of hospitals, medical office buildings, skilled nursing facilities, senior living facilities, and biotech and pharmaceutical laboratories. HCP manages over 1,000 properties and has $22 billion in assets under management.

Health Care Property Investors trades publicly on the New York Stock Exchange under the ticker symbol HCP, is a member of the S&P 500, is #941 in the Fortune 1000, has 170 employees, and had $2.53 billion in revenue in 2014.

 

 

Health Care Property Investors

Health Care Property Investors is a real-estate investment trust (REIT) that was founded in 1985. The company originally invested primarily in health care real estate. Hospitals and Post-Acute Care facilities were in the original portfolio.

Today Health Care Property Investors (HCP) invests in, develops, manages, and leases health care properties in 40 U.S. states and Mexico.

Its real estate portfolio consists of hospitals, medical office buildings, skilled nursing facilities, senior living facilities, and biotech and pharmaceutical laboratories. HCP manages over 1,000 properties and has $22 billion in assets under management.

History

Health Care Property Investors trades publicly on the New York Stock Exchange under the ticker symbol HCP, is a member of the S&P 500, is #941 in the Fortune 1000, has 170 employees, and had $2.53 billion in revenue in 2014.

 

 

Stericycle Corporate Office

Stericycle was founded as a medical waste disposal company in 1989 and became publicly traded in 1996.

The company is most well-known for the 2013 scandal in which Erin Brockovich teamed up with local Utah residents in criticizing Stericycle for polluting by burning hazardous radioactive waste at their incinerator in the state. An investigation subsequently found toxic levels of Dioxin in homes near the incinerator.

Today Stericycle serves over 540,000 clients worldwide, including 16,500 waste generators such as pharmaceutical manufacturers, hospitals, and blood banks, and 524,500 small waste generators such as pharmacies, municipalities, dental offices, medical offices, and veterinary offices.

Stericycle trades publicly on the NASDAQ under the ticker symbol SRLC, is a member of the S&P 500, is #932 in the Fortune 1000, has 16,700 employees, and had $2.65 billion in revenue in 2014.

Stericycle

Stericycle was founded as a medical waste disposal company in 1989 and became publicly traded in 1996.

The company is most well-known for the 2013 scandal in which Erin Brockovich teamed up with local Utah residents in criticizing Stericycle for polluting by burning hazardous radioactive waste at their incinerator in the state. An investigation subsequently found toxic levels of Dioxin in homes near the incinerator.

Today Stericycle serves over 540,000 clients worldwide, including 16,500 waste generators such as pharmaceutical manufacturers, hospitals, and blood banks, and 524,500 small waste generators such as pharmacies, municipalities, dental offices, medical offices, and veterinary offices.

History

Stericycle trades publicly on the NASDAQ under the ticker symbol SRLC, is a member of the S&P 500, is #932 in the Fortune 1000, has 16,700 employees, and had $2.65 billion in revenue in 2014.

PerkinElmer/Revvity Corporate Office

PerkinElmer was founded by Charles Elmer and Richard Perkin in 1937.  The company operated originally as an optical design and consulting company and transitioned to the analytical instruments business in 1944.

In 1999 the company merged with EG&G Inc. The new company kept the PerkinElmer name.

Today PerkinElmer designs, produces, and markets equipment used by researchers to identify and treat diseases as well as analyze food products and identify contaminants in air, water, and soil.

PerkinElmer trades publicly on the New York Stock Exchange under the ticker symbol RVTY, is a member of the S&P 500, is #920 in the Fortune 1000, has 16,700 employees, and had $2.24 billion in revenue in 2014.

In March 2021, PerkinElmer announced that the company had completed its acquisition of Oxford Immunotec Global PLC (Oxford Immunotec) and in May of the same year, the business announced it would purchase Nexcelom Bioscience for $260 million and Immunodiagnostic Systems Holdings PLC for $155 million. 

In May 2023, the company sold off part of its Food and Enterprise Services division, along with its name. PerkinElmer has rebranded itself as Revvity. 

Revvity maintains a corporate office in Waltham, Massachusetts.

PerkinElmer/Revvity

PerkinElmer was founded by Charles Elmer and Richard Perkin in 1937.  The company operated originally as an optical design and consulting company and transitioned to the analytical instruments business in 1944.

In 1999 the company merged with EG&G Inc. The new company kept the PerkinElmer name.

History

Today PerkinElmer designs, produces, and markets equipment used by researchers to identify and treat diseases as well as analyze food products and identify contaminants in air, water, and soil.

PerkinElmer trades publicly on the New York Stock Exchange under the ticker symbol RVTY, is a member of the S&P 500, is #920 in the Fortune 1000, has 16,700 employees, and had $2.24 billion in revenue in 2014.

In March 2021, PerkinElmer announced that the company had completed its acquisition of Oxford Immunotec Global PLC (Oxford Immunotec) and in May of the same year, the business announced it would purchase Nexcelom Bioscience for $260 million and Immunodiagnostic Systems Holdings PLC for $155 million. 

In May 2023, the company sold off part of its Food and Enterprise Services division, along with its name. PerkinElmer has rebranded itself as Revvity. 

Revvity maintains a corporate office in Waltham, Massachusetts.